Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00623727 · ClinicalTrials.gov registry record · Phase 2
BAY79-4980 Compared to rFVIII-FS in Previously Treated Patients With Severe Hemophilia A
A Phase 2 study, sponsored by Bayer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 143
- Enrollment target
NCT00623727 is a Phase 2 study that was terminated before completion, run by Bayer. The registered enrollment target is 143 participants.
The verdict
NCT00623727, a Phase 2 study, was terminated before completion, sponsored by Bayer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 143 participants
- Enrollment target
Study Summary
A study to assess treatment with a new formulation of recombinant factor VIII reconstituted with liposomes (BAY79-4980) to evaluate whether a once-a-week treatment is safe and can prevent bleeds in subjects with severe haemophilia A.
Interventions
- BIOLOGICAL rFVIII-FS/pegylated liposomes (BAY79-4980)
- BIOLOGICAL rFVIII-FS/WFI (BAY14-2222)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 143 participants |
| Start Date | 2008-06 |
| Est. Completion | 2010-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00623727
The ClinicalTrials.gov registry entry for NCT00623727 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 143 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which rFVIII-FS/pegylated liposomes (BAY79-4980) is the first listed.
NCT00623727 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00623727 about?
NCT00623727 is a clinical study titled "BAY79-4980 Compared to rFVIII-FS in Previously Treated Patients With Severe Hemophilia A". A study to assess treatment with a new formulation of recombinant factor VIII reconstituted with liposomes (BAY79-4980) to evaluate whether a once-a-week treatment is safe and can prevent bleeds in subjects with severe haemophilia A.
What is the current status of trial NCT00623727?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 143 participants. The study started on 2008-06. Estimated completion is 2010-10.
What interventions are being tested in trial NCT00623727?
The interventions under investigation include: rFVIII-FS/pegylated liposomes (BAY79-4980) (BIOLOGICAL), rFVIII-FS/WFI (BAY14-2222) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00623727?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.